Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleExperimental Studies

The Predominant CD44 Splice Variant in Prostate Cancer Binds Fibronectin, and Calcitonin Stimulates its Expression

KENNETH A. ICZKOWSKI, A. LEVI OMARA-OPYENE and GIRISH V. SHAH
Anticancer Research July 2006, 26 (4B) 2863-2872;
KENNETH A. ICZKOWSKI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: iczkoka{at}pathology.ufl.edu
A. LEVI OMARA-OPYENE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
GIRISH V. SHAH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Background: Prostate cancer (PC) consistently overexpresses variant the (v) isoform of the cell adhesion protein CD44, and loses expression of the standard (s) isoform. Materials and Methods: We re-expressed CD44 full-length (exons 1-20) or standard (exons 1-5 + 16-20) or enforced stable RNAi against CD44v, and the examined functional effects on PC. The effect of stable knockout of calcitonin, a paracrine factor, or its receptor, on CD44 was assessed. Results: Re-expression of full-length CD44 or CD44s increased the total CD44 mRNA and CD44s protein while suppressing CD44v. These approaches, and RNAi to CD44v, decreased invasion. In adhesion assays, benign prostate cells bound mainly to hyaluronan, whereas PC lost affinity for hyaluronan but bound more strongly to fibronectin. Re-expressing CD44s restored predominant hyaluronan binding. Knockout of the calcitonin receptor in PC-3 derived cells caused marked loss of CD44v expression and reversion to CD44s expression. Conclusion: Calcitonin influenced PC's balance between CD44s and CD44v. CD44v controlled invasiveness, altered ligand binding, and provides a target for therapeutic intervention.

  • Adhesion
  • CD44
  • invasion
  • prostate cancer

Footnotes

  • Abbreviations: CD44s - CD44, standard isoform; CD44v - CD44, variant isoform; GFP, green fluorescent protein; PC, prostate cancer; RNAi, RNA interference; SD, standard deviation.

  • Received April 28, 2006.
  • Accepted May 8, 2006.
  • Copyright© 2006 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved
PreviousNext
Back to top

In this issue

Anticancer Research
Vol. 26, Issue 4B
July-August 2006
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The Predominant CD44 Splice Variant in Prostate Cancer Binds Fibronectin, and Calcitonin Stimulates its Expression
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
9 + 0 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
The Predominant CD44 Splice Variant in Prostate Cancer Binds Fibronectin, and Calcitonin Stimulates its Expression
KENNETH A. ICZKOWSKI, A. LEVI OMARA-OPYENE, GIRISH V. SHAH
Anticancer Research Jul 2006, 26 (4B) 2863-2872;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
The Predominant CD44 Splice Variant in Prostate Cancer Binds Fibronectin, and Calcitonin Stimulates its Expression
KENNETH A. ICZKOWSKI, A. LEVI OMARA-OPYENE, GIRISH V. SHAH
Anticancer Research Jul 2006, 26 (4B) 2863-2872;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

Cited By...

  • Glycoproteogenomics characterizes the CD44 splicing code driving bladder cancer invasion
  • Evaluation of the Prognostic Value of CD44 in Glioblastoma Multiforme
  • Google Scholar

More in this TOC Section

  • Ginsenoside Rd Improves Anticancer Drug-induced Disturbance in Murine Airway Ciliary Motility
  • Association of Matrix Metalloproteinase-11 Genotypes With Taiwan Gastric Cancer Risk and Clinical Features
  • Methionine Restriction, Not Cysteine Restriction, Is a Cancer-specific Vulnerability
Show more Experimental Studies
Anticancer Research

© 2026 Anticancer Research

Powered by HighWire